Rigor before speculation in COVID-19 therapy
Am J Physiol Lung Cell Mol Physiol
.
2020 May 1;318(5):L1027-L1028.
doi: 10.1152/ajplung.00152.2020.
Authors
Paul A Welling
1
2
,
Daniel Batlle
3
,
James Brian Byrd
4
,
Louise M Burrell
5
,
Andrew M South
6
,
Matthew A Sparks
7
Affiliations
1
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
2
Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
3
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
4
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
5
Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
6
Wake Forest School of Medicine, Winston Salem, North Carolina.
7
Department of Medicine, Duke University School of Medicine, and Durham Veterans Affairs Medical Centers, Durham, North Carolina.
PMID:
32364442
PMCID:
PMC7203572
DOI:
10.1152/ajplung.00152.2020
No abstract available
Publication types
Letter
Comment
MeSH terms
Betacoronavirus*
COVID-19
Coronavirus Infections*
Humans
Pandemics
Pneumonia, Viral*
SARS-CoV-2
Grants and funding
L40 HL148910/HL/NHLBI NIH HHS/United States
R01 DK104785/DK/NIDDK NIH HHS/United States
R01 HL146818/HL/NHLBI NIH HHS/United States